Oncology Patients' Perspectives on Remote Patient Monitoring for COVID-19.
Journal
JCO oncology practice
ISSN: 2688-1535
Titre abrégé: JCO Oncol Pract
Pays: United States
ID NLM: 101758685
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
pubmed:
5
6
2021
medline:
16
9
2021
entrez:
4
6
2021
Statut:
ppublish
Résumé
Oncology patients are vulnerable to adverse outcomes associated with COVID-19, and clinical deterioration must be identified early. Several institutions launched remote patient monitoring programs (RPMPs) to care for patients with COVID-19. We describe patients' perspectives on a COVID-19 RPMP at a National Comprehensive Cancer Center. Patients who tested positive for COVID-19 were eligible. Enrolled patients received a daily electronic COVID-19 symptom assessment, and a subset of high-risk patients also received a pulse oximeter. Monitoring was provided by a centralized team and was discontinued 14 days after a patient's positive test result and following 3 days without worsening symptoms. Patients who completed at least one assessment and exited the program were sent a patient engagement survey to evaluate the patient's experience with digital monitoring for COVID-19. The survey was distributed to 491 patients, and 257 responded (52% completion rate). The net promoter score was 85%. Most patients agreed that the RPMP was worthwhile, enabled better management of their COVID-19 symptoms, made them feel more connected to their healthcare team, and helped prevent emergency room visits. Identified themes regarding patient-perceived value of a RPMP included (1) security: a clinical safety net; (2) connection: a link to their clinical team during a period of isolation; and (3) empowerment: an education on the virus and symptom management. RPMPs are perceived to be of value to oncology patients with COVID-19. Policymakers should consider how these programs can be reimbursed to keep vulnerable patients at home and out of the acute care setting.
Identifiants
pubmed: 34085536
doi: 10.1200/OP.21.00269
pmc: PMC8457795
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
e1278-e1285Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Références
Otolaryngol Head Neck Surg. 2005 Aug;133(2):169-72
pubmed: 16087007
JCO Oncol Pract. 2021 Sep;17(9):e1286-e1292
pubmed: 33793345
J Oncol Pract. 2018 Aug;14(8):e484-e495
pubmed: 30016125
Appl Clin Inform. 2020 Oct;11(5):792-801
pubmed: 33241547
BMJ. 2000 Jan 8;320(7227):114-6
pubmed: 10625273
Lancet Oncol. 2020 May;21(5):e240-e251
pubmed: 32359500
BMJ Open. 2019 Sep 17;9(9):e030863
pubmed: 31530612
Lancet Oncol. 2020 Mar;21(3):335-337
pubmed: 32066541
JAMA. 2017 Jul 11;318(2):197-198
pubmed: 28586821
JCO Oncol Pract. 2020 Oct;16(10):e1050-e1059
pubmed: 32468925
BMJ Open. 2020 Oct 23;10(10):e037641
pubmed: 33099495
N Engl J Med. 2021 Apr 15;384(15):1384-1386
pubmed: 33853209
J Oncol Pract. 2015 Sep;11(5):410-5
pubmed: 26152375
Lancet. 2020 Jun 20;395(10241):1907-1918
pubmed: 32473681
Harv Bus Rev. 2003 Dec;81(12):46-54, 124
pubmed: 14712543
Ann Oncol. 2020 Oct;31(10):1386-1396
pubmed: 32561401
J Oncol Pract. 2016 May;12(5):e594-602
pubmed: 27048613
JAMA Oncol. 2020 Jul 1;6(7):1108-1110
pubmed: 32211820
J Clin Oncol. 2016 Feb 20;34(6):557-65
pubmed: 26644527
J Am Med Inform Assoc. 2020 Aug 1;27(8):1326-1330
pubmed: 32392280
J Am Med Inform Assoc. 2020 Nov 1;27(11):1825-1827
pubmed: 32667985